New preclinical data extend the trivalent mRNA approach to HSV-1 eye disease
Published:
A peer-reviewed mouse study from the University of Pennsylvania group behind the trivalent gC2/gD2/gE2 mRNA design — the approach licensed to BioNTech as BNT163 — reported that the vaccine protected against HSV-1 eye infection and spread to the nervous system in mice. The findings are preclinical (in animals) and broaden the trivalent rationale beyond genital HSV-2; on their own they are not evidence of protection in people.
A new peer-reviewed paper from the University of Pennsylvania laboratory behind the trivalent gC2/gD2/gE2 mRNA approach — the design licensed to BioNTech and now in the clinic as BNT163 — reports that the vaccine protected mice against HSV-1 infection of the eye and against neuroinvasion, the virus’s spread into the nervous system.
This extends the trivalent design’s evidence base beyond genital HSV-2, the setting it was first built for. The important qualifier is the model: these are preclinical results in animals. They strengthen the preclinical rationale for the platform; they do not, by themselves, show that the vaccine protects people — that question is still being tested in the Phase 1 trial of BNT163. See the research entry for details.